Bactolife will use the donation to continue the development of Binding Proteins, its proprietary biologic solution that reduces gut infection risk.
“With this investment, Bactolife is able to boost our efforts in our technology platform, allowing us to reach our end customers faster and with affordable products that can benefit the many – thereby potentially impacting millions of peoples’ lives worldwide,” Mads Lautsen, Bactolife’s CEO, said in an Aug. 30 press release from Bactolife’s holding company Novo Holdings.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
